{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T09:38:41Z","timestamp":1792834721785,"version":"4.5.0"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"35","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,28]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Crohn disease (CD) and ulcerative colitis (UC) are chronic inflammatory bowel diseases characterized by immune dysregulation. Despite biologic advancements, many patients experience treatment failure. Risankizumab (RZB), a selective interleukin-23 inhibitor, has emerged as a promising therapy for moderate-to-severe inflammatory bowel diseases. This systematic review evaluates its efficacy, safety, and therapeutic outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, a systematic search of PubMed, Embase, Scopus, and ClinicalTrials.gov was conducted to identify studies published up to 2025. Eligible studies included randomized controlled trials, clinical trials, and retrospective observational studies evaluating RZB in adult patients with CD or UC. Primary outcomes included clinical remission, endoscopic response, hospitalization rates, and adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Seventeen studies involving 6602 patients (5627 with CD, 975 with UC) were analyzed. In CD, RZB demonstrated high clinical remission rates, endoscopic healing, and reduced hospitalizations, including in biologic-refractory patients. In UC, it showed significant remission rates and fewer UC-related hospitalizations. RZB was well tolerated, with mostly mild to moderate adverse events such as arthralgia, headache, and nasopharyngitis. Severe adverse events were rare.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>RZB is an effective and well-tolerated treatment for moderate-to-severe CD and UC, showing strong clinical and endoscopic outcomes. It offers a viable option for biologic-refractory patients, but further research is needed to assess long-term efficacy and safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000050434","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T02:00:09Z","timestamp":1787968809000},"page":"e50434","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy, safety and outcome of selective IL-23 inhibitor risankizumab in induction and maintenance of CD and ulcerative colitis"],"prefix":"10.1097","volume":"105","author":[{"given":"Muhammad Waqas","family":"Afzal","sequence":"first","affiliation":[{"name":"Department of Medicine, Ibn e Seena Hospital, Kabul, Afghanistan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul","family":"Haseeb","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ibn e Seena Hospital, Kabul, Afghanistan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ushna","family":"Ali","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ibn e Seena Hospital, Kabul, Afghanistan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Rizwan","family":"Ashraf","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ibn e Seena Hospital, Kabul, Afghanistan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asad","family":"Mehmood","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ibn e Seena Hospital, Kabul, Afghanistan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3310-5442","authenticated-orcid":false,"given":"Abida","family":"Perveen","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ibn e Seena Hospital, Kabul, Afghanistan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261024","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1093\/ibd\/izad315","article-title":"Real-world effectiveness and safety of risankizumab in patients with moderate-to-severe multirefractory Crohn\u2019s disease: a belgian multicentric cohort study.","volume":"30","author":"Alsoud","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"R2-20261024","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa2314585","article-title":"Risankizumab versus ustekinumab for moderate-to-severe Crohn\u2019s disease.","volume":"391","author":"Peyrin-Biroulet","year":"2024","journal-title":"N Engl J Med"},{"issue":"Supplement_1","key":"R3-20261024","doi-asserted-by":"crossref","first-page":"i2047","DOI":"10.1093\/ecco-jcc\/jjae190.1289","article-title":"P1115 short- and mid-term effectiveness and safety of risankizumab in refractory Crohn\u2019s disease: a retrospective study.","volume":"19","author":"Elosua Gonzalez","year":"2025","journal-title":"J Crohns Colitis"},{"issue":"Supplement_1","key":"R4-20261024","doi-asserted-by":"crossref","first-page":"i2021","DOI":"10.1093\/ecco-jcc\/jjae190.1274","article-title":"P1100 effectiveness of risankizumab in Crohn\u2019s disease, our real-world experience: clinical, biochemical and ultrasonographic responses. a single centre, observational, retrospective study.","volume":"19","author":"Moralejo Lozano","year":"2025","journal-title":"J Crohns Colitis"},{"key":"R5-20261024","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/jgh.16358","article-title":"Efficacy and safety of risankizumab for Crohn\u2019s disease in patients from Asian countries: a post hoc subanalysis of the global phase 3 ADVANCE, MOTIVATE, and FORTIFY studies.","volume":"39","author":"Gao","year":"2024","journal-title":"J Gastroenterol Hepatol"},{"key":"R6-20261024","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0140-6736(22)00467-6","article-title":"Risankizumab as induction therapy for Crohn\u2019s disease: results from the phase 3 ADVANCE and MOTIVATE induction trials.","volume":"399","author":"D\u2019Haens","year":"2022","journal-title":"Lancet"},{"key":"R7-20261024","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S2468-1253(18)30233-4","article-title":"Risankizumab in patients with moderate-to-severe Crohn\u2019s disease: an open-label extension study.","volume":"3","author":"Feagan","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R8-20261024","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(22)00466-4","article-title":"Risankizumab as maintenance therapy for moderately to severely active Crohn\u2019s disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.","volume":"399","author":"Ferrante","year":"2022","journal-title":"Lancet"},{"key":"R9-20261024","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1093\/ecco-jcc\/jjab093","article-title":"Long-term safety and efficacy of risankizumab treatment in patients with Crohn\u2019s disease: results from the phase 2 open-label extension study.","volume":"15","author":"Ferrante","year":"2021","journal-title":"J Crohns Colitis"},{"issue":"Supplement_1","key":"R10-20261024","doi-asserted-by":"crossref","first-page":"i381","DOI":"10.1093\/ecco-jcc\/jjab232.507","article-title":"P380 Early improvement of endoscopic outcomes with risankizumab is associated with reduced hospitalisation and surgery rates in patients with Crohn\u2019s disease.","volume":"16","author":"Feagan","year":"2022","journal-title":"J Crohns Colitis"},{"key":"R11-20261024","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1016\/j.cgh.2024.04.016","article-title":"Long-term outcome of risankizumab in Crohn\u2019s disease: a real-world GETAID study.","volume":"22","author":"Fumery","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R12-20261024","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/S0140-6736(17)30570-6","article-title":"Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn\u2019s disease: a randomised, double-blind, placebo-controlled phase 2 study.","volume":"389","author":"Feagan","year":"2017","journal-title":"Lancet"},{"key":"R13-20261024","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/apt.17242","article-title":"Effect of risankizumab on health-related quality of life in patients with Crohn\u2019s disease: results from phase 3 MOTIVATE, ADVANCE and FORTIFY clinical trials.","volume":"57","author":"Peyrin-Biroulet","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"issue":"Supplement_1","key":"R14-20261024","doi-asserted-by":"crossref","first-page":"S026","DOI":"10.1093\/ecco-jcc\/jjab075.025","article-title":"OP26 Risankizumab induces early clinical remission and response in patients with moderate-to-severe Crohn\u2019s Disease: results from the phase 3 ADVANCE and MOTIVATE studies.","volume":"15","author":"Schreiber","year":"2021","journal-title":"J Crohns Colitis"},{"key":"R15-20261024","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/jama.2024.12414","article-title":"Risankizumab for ulcerative colitis: two randomized clinical trials.","volume":"332","author":"Louis","year":"2024","journal-title":"JAMA"},{"issue":"Supplement_1","key":"R16-20261024","doi-asserted-by":"crossref","first-page":"i1288","DOI":"10.1093\/ecco-jcc\/jjad212.0813","article-title":"P683 Economic impact of achieving mucosal healing on UC-related hospitalisations and work productivity in patients with moderately to severely active UC: a post-hoc analysis of risankizumab phase 2b\/3 trials.","volume":"18","author":"Peyrin-Biroulet","year":"2024","journal-title":"J Crohns Colitis"},{"issue":"12 Suppl 9","key":"R17-20261024","first-page":"9","article-title":"Risankizumab induction therapy in patients with moderately to severely active ulcerative colitis: efficacy and safety in the randomized phase 3 INSPIRE study.","volume":"19","year":"2023","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"R19-20261024","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.3390\/jcm12072452","article-title":"Recent advances in the optimization of anti-TNF treatment in patients with inflammatory bowel disease.","volume":"12","author":"Orfanoudaki","year":"2023","journal-title":"J Clin Med"},{"key":"R20-20261024","doi-asserted-by":"crossref","first-page":"10172","DOI":"10.3390\/ijms241210172","article-title":"The role of IL-23 in the pathogenesis and therapy of inflammatory bowel disease.","volume":"24","author":"Korta","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R21-20261024","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1111\/ijd.17156","article-title":"Effectiveness of risankizumab for the treatment of psoriatic arthritis: a multicenter, real-world study.","volume":"63","author":"Graceffa","year":"2024","journal-title":"Int J Dermatol"},{"key":"R22-20261024","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1111\/jdv.14433","article-title":"The role of IL-23 and the IL-23\/TH 17 immune axis in the pathogenesis and treatment of psoriasis.","volume":"31","author":"Girolomoni","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R23-20261024","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.3390\/biomedicines11082249","article-title":"Inflammatory bowel disease: emerging therapies and future treatment strategies.","volume":"11","author":"Bretto","year":"2023","journal-title":"Biomedicines"},{"issue":"Supplement_2","key":"R24-20261024","doi-asserted-by":"crossref","first-page":"ii3","DOI":"10.1093\/ecco-jcc\/jjac034","article-title":"Interleukin-23 in the pathogenesis of inflammatory bowel disease and implications for therapeutic intervention.","volume":"16","author":"Sewell","year":"2022","journal-title":"J Crohns Colitis"},{"key":"R25-20261024","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1007\/s40265-017-0794-1","article-title":"Selective interleukin-23 p19 inhibition: another game changer in psoriasis? Focus on risankizumab.","volume":"77","author":"Torres","year":"2017","journal-title":"Drugs"},{"key":"R26-20261024","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1007\/s10620-023-08014-z","article-title":"Efficacy and safety of IL-12\/23 and IL-23 inhibitors for Crohn\u2019s disease: systematic review and meta-analysis.","volume":"68","author":"Vuyyuru","year":"2023","journal-title":"Dig Dis Sci"},{"key":"R27-20261024","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1007\/s40265-023-01942-0","article-title":"Escalation versus induction\/high-efficacy treatment strategies for relapsing multiple sclerosis: which is best for patients?","volume":"83","author":"Edan","year":"2023","journal-title":"Drugs"},{"key":"R28-20261024","doi-asserted-by":"crossref","first-page":"100544","DOI":"10.1016\/j.gastha.2024.08.022","article-title":"Early endoscopic outcomes after risankizumab are associated with fewer hospitalizations and surgeries in Crohn\u2019s disease.","volume":"4","author":"Feagan","year":"2025","journal-title":"Gastro Hep Adv"},{"issue":"Supplement_2","key":"R29-20261024","doi-asserted-by":"crossref","first-page":"ii64","DOI":"10.1093\/ecco-jcc\/jjab185","article-title":"Blockade of IL-23: what is in the pipeline?","volume":"16","author":"Parigi","year":"2022","journal-title":"J Crohns Colitis"},{"key":"R30-20261024","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3390\/antib13030076","article-title":"Therapeutic advances in psoriasis: from biologics to emerging oral small molecules.","volume":"13","author":"Ferrara","year":"2024","journal-title":"Antibodies (Basel)"},{"key":"R31-20261024","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/ueg2.12202","article-title":"Endoscopy and histology in inflammatory bowel diseases patients: complementary or alternatives?","volume":"10","author":"D\u2019Amico","year":"2022","journal-title":"United European Gastroenterol J"},{"key":"R32-20261024","doi-asserted-by":"crossref","first-page":"7026","DOI":"10.3390\/jcm13237026","article-title":"Optimal management of patients with moderate-to-severe inflammatory bowel disease.","volume":"13","author":"Purnak","year":"2024","journal-title":"J Clin Med"},{"key":"R33-20261024","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/bjd.20818","article-title":"Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis.","volume":"186","author":"Gordon","year":"2022","journal-title":"Br J Dermatol"},{"issue":"Supplement_2","key":"R34-20261024","doi-asserted-by":"crossref","first-page":"ii54","DOI":"10.1093\/ecco-jcc\/jjac007","article-title":"IL-23 blockade in Anti-TNF refractory IBD: from mechanisms to clinical reality.","volume":"16","author":"Atreya","year":"2022","journal-title":"J Crohns Colitis"},{"key":"R35-20261024","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1007\/s12325-023-02546-6","article-title":"Matching-adjusted indirect comparison between risankizumab and ustekinumab for induction and maintenance treatment of moderately to severely active Crohn\u2019s disease.","volume":"40","author":"Dubinsky","year":"2023","journal-title":"Adv Ther"},{"key":"R36-20261024","doi-asserted-by":"crossref","first-page":"581","DOI":"10.2217\/imt-2023-0219","article-title":"Positioning risankizumab in the treatment algorithm of moderate-to-severe Crohn\u2019s disease.","volume":"16","author":"Lusetti","year":"2024","journal-title":"Immunotherapy"},{"key":"R37-20261024","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1007\/s13555-024-01292-z","article-title":"Efficacy and safety of risankizumab in patients with psoriasis showing suboptimal response to secukinumab or ixekizumab: results from a phase 3b, open-label, single-arm (aIMM) Study.","volume":"14","author":"Warren","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"key":"R38-20261024","doi-asserted-by":"crossref","first-page":"17562848241309871","DOI":"10.1177\/17562848241309871","article-title":"Advancements in dual biologic therapy for inflammatory bowel diseases: efficacy, safety, and future directions.","volume":"18","author":"Fabisiak","year":"2025","journal-title":"Ther Adv Gastroenterol"},{"key":"R39-20261024","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1002\/cpt.2103","article-title":"The evidence REVEAL study: exploring the use of real-world evidence and complex clinical trial design by the european pharmaceutical industry.","volume":"110","author":"Varnai","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"R40-20261024","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2147\/CEG.S360248","article-title":"Personalized treatment for Crohn\u2019s disease: current approaches and future directions.","volume":"16","author":"Clinton","year":"2023","journal-title":"Clin Exp Gastroenterol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050434","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T09:00:48Z","timestamp":1792832448000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050434"}},"subtitle":["A systematic review"],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":39,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000050434","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]},"assertion":[{"value":"2025-05-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-12","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}